DoD Breast Cancer, Breakthrough Award Levels 1 and 2 | HT942524BCRPBTA122

Opportunity Information: Apply for HT942524BCRPBTA122

The Department of Defense (DoD) Breast Cancer Breakthrough Award Levels 1 and 2 aim to support innovative and high-impact research with the potential to significantly advance breast cancer understanding, treatment, or prevention. The program is part of the Congressionally Directed Medical Research Programs (CDMRP) under the Breast Cancer Research Program (BCRP) and is structured to fund research at different stages of development.

### Key Components:

#### **Impact & Scope** Research funded under this opportunity should offer more than incremental advancements and must have the potential to drive significant progress in breast cancer research. Projects should clearly define the patient population that would benefit.

The program includes multiple funding levels, with the current announcement covering **Funding Levels 1 and 2**: - **Level 1**: High-risk, high-reward research at an early stage of development; no preliminary data required. - **Level 2**: Research supported by strong preliminary or published data with a clear path toward clinical translation in the breast cancer field. - **Level 2 (Population Science and Prevention Studies)**: Investigates variations in cancer risk or prognosis using human data and biospecimens, with an option for higher funding and an extended performance period.

#### **Funding & Budget** - **Level 1**: Up to **$450,000** for a single Principal Investigator (PI); **$750,000** under the Partnering PI Option. - **Level 2**: Up to **$1.0M** for a single PI; **$1.5M** under the Partnering PI Option. - **Level 2 (Population Science and Prevention Studies)**: Up to **$1.5M** for a single PI; **$2.0M** under the Partnering PI Option. - Approximately **$12.6M** in funding is expected to support around eight awards.

#### **Partnering PI Option** Allows two investigators to collaborate on a proposal, bringing distinct expertise and contributing equally to project execution. The funding is expected to be balanced between both PIs unless justified otherwise.

#### **Additional Considerations** - **Clinical trials are not allowed**, but research involving human subjects or biospecimens is permitted. - The program encourages research addressing metastatic breast cancer, precision imaging, nuclear medicine applications, and women’s health disparities. - Collaboration between military and non-military research institutions is strongly encouraged. - Awards are expected to be issued by September 30, 2025, and are funded with fiscal year 2024 (FY24) funds, expiring September 30, 2030.

This funding opportunity aims to accelerate scientific breakthroughs that can lead to meaningful progress in breast cancer prevention, diagnosis, and treatment. Researchers are advised to select the appropriate funding level based on the scope of their work rather than budget constraints.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Levels 1 and 2" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-11.
• Applicants must submit their applications by 2024-09-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2025.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524BCRPBTA122

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: